Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Drop in Short Interest

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 174,100 shares, a decline of 80.8% from the January 15th total of 909,000 shares. Based on an average daily volume of 4,260,000 shares, the short-interest ratio is presently 0.0 days. Currently, 1.6% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “neutral” rating and set a $7.00 price target on shares of Windtree Therapeutics in a research report on Wednesday, December 4th.

Windtree Therapeutics Trading Down 9.5 %

NASDAQ WINT opened at $0.15 on Friday. The stock has a market capitalization of $1.70 million, a price-to-earnings ratio of -0.01 and a beta of 0.53. The stock has a 50-day moving average of $0.26 and a 200 day moving average of $2.60. Windtree Therapeutics has a twelve month low of $0.10 and a twelve month high of $14.75.

Windtree Therapeutics (NASDAQ:WINT) last posted its quarterly earnings data on Tuesday, November 26th. The company reported ($4.23) EPS for the quarter, missing analysts’ consensus estimates of ($2.27) by ($1.96). Equities analysts predict that Windtree Therapeutics will post -5.66 EPS for the current fiscal year.

Hedge Funds Weigh In On Windtree Therapeutics

A hedge fund recently bought a new stake in Windtree Therapeutics stock. Renaissance Technologies LLC bought a new position in shares of Windtree Therapeutics, Inc. (NASDAQ:WINT) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned approximately 1.08% of Windtree Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 29.33% of the company’s stock.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.